Clinical Trials Logo

Filter by:
NCT ID: NCT01410058 Completed - HIV Clinical Trials

Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction

Start date: January 2013
Phase:
Study type: Observational

A study will be conducted by scientists from the University of Zimbabwe to determine if antiretroviral drugs are affected by taking herbs at the same time. This is important because herbal medicines may interact with modern medicine to increase or decrease the amount of medication in the body. The drugs nevirapine and efavirenz will be studied. Both drugs are routinely used as part of combination therapy for treating HIV. In this study it will be determined whether the concentrations of the antiretroviral drugs nevirapine and efavirenz are low, high or are in the desired range when taken together with the herb moringa.

NCT ID: NCT01404312 Completed - HIV Infections Clinical Trials

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Start date: May 23, 2012
Phase: Phase 3
Study type: Interventional

HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety and effectiveness of a 4-week regimen of rifapentine (RPT) plus INH versus a standard 9-month regimen of INH in HIV-infected people who are at risk of developing active TB.

NCT ID: NCT01380080 Completed - HIV Infection Clinical Trials

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

REMEMBER
Start date: October 2011
Phase: Phase 4
Study type: Interventional

People with HIV have a high chance of becoming infected with TB, especially when they live in areas where TB infection is common. It can be difficult to diagnose TB in people who need to start HIV treatment right away. Within about 6 months after starting HIV treatment, some of these people can become very sick with TB and can even die from it. This study was being done in people who were starting HIV treatment and who lived in areas where the TB infection rate is high. The purpose of this study was to test an experimental approach to TB treatment to see if it is better than the usual approach. The experimental approach was to start TB treatment at the same time as HIV treatment, even when TB infection had not been found. The usual approach was to start TB treatment only if TB infection was found. In this study, half of the people started TB treatment at the same time as they started their HIV treatment. The other half started TB treatment only if TB infection was found. The study also tested how safe and effective it was to start TB treatment at about the same time as HIV treatment even when TB infection had not been found. The study collected information about diet, whether (and when) people in the study became sicker or died, how well their HIV was controlled, how they were feeling, how they were taking their medications, whether it mattered where they lived or what kind of HIV and TB care was standard, how many people were diagnosed with TB while in the study, and how the cost of the two treatment options on a national level could be compared.

NCT ID: NCT01352715 Completed - HIV-1 Infection Clinical Trials

Study of Options for Second-Line Effective Combination Therapy (SELECT)

SELECT
Start date: March 13, 2012
Phase: Phase 3
Study type: Interventional

The study was conducted on people who were taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), a type of anti-HIV drug) but the drugs in this regimen were not doing a good job of fighting their HIV infection. The main purpose of this study was to compare two other anti-HIV drug regimens to see how well they fight HIV. The study also looked at how well participants tolerate the drug regimens and how safe they are. The study was designed to determine whether taking the combination of lopinavir/ritonavir (LPV/r) plus raltegravir (RAL) works as well as what is usually used for second-line therapy: LPV/r plus the best-available nucleoside (nucleotide) reverse transcriptase inhibitor (NRTI) combination. Testing a regimen that does not include any NRTIs was important because NRTIs may no longer work for patients who received them as part of their first treatment regimen.

NCT ID: NCT01337570 Withdrawn - HIV Infections Clinical Trials

A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa

Start date: July 2011
Phase: Phase 3
Study type: Interventional

This is a double-blind, randomized, placebo-controlled Phase III study to assess the safety and efficacy of a silicone elastomer vaginal ring containing 25mg of dapivirine.

NCT ID: NCT01315353 Completed - HIV-1 Infection Clinical Trials

HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women

Start date: April 4, 2012
Phase: N/A
Study type: Interventional

Women sometimes develop cancer in an area called the cervix, which is the opening to the uterus, or womb. Women who have HIV are more likely to get this kind of cancer than women who do not have HIV. Nearly all of these cancers are caused by another virus, called human papilloma virus (or HPV). Other times, the cause of this cancer is not known. The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to prevent cancer of the cervix in women who have HIV. This study will also see if these methods are safe and tolerable in women who have HIV.

NCT ID: NCT01306383 Completed - Diarrhoea Clinical Trials

Solar Disinfection (SODIS) of Drinking Water for Use in Developing Countries or in Emergency Situations

SODISWATER
Start date: June 2008
Phase: N/A
Study type: Interventional

SODISWATER was a health impact assessment study investigating the effect of sunlight to inactivate microbial pathogens in drinking water. This study was carried out by observing whether children younger than 5 years old who drink solar disinfected water were healthier than those who did not. Health was measured by how often the children had diarrhoea or dysentery. Caregivers for the participants were given plastic bottles to place in the sun, water samples were then collected from these plastic bottles to be analyzed. They were also requested to fill in diarrhea diaries. TESTABLE RESEARCH HYPOTHESES: Health Impact Assessment: Children who use solar disinfected water will have: (a) lower morbidity due to non-bloody diarrhoea and bloody diarrhoea (c) increased growth rates (d) lower mortality (e) increased family productivity (f) decreased care-giver burden (g) increased school attendance

NCT ID: NCT01302847 Completed - HIV Infections Clinical Trials

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Start date: April 20, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy (OBT) in HIV-1 infected infants, children, and adolescents.

NCT ID: NCT01283165 Completed - Clinical trials for Integrated Control of Malaria and Polyparasitism

Worm Infestation and Child Health in Zimbabwe

Zimworms
Start date: April 2003
Phase: N/A
Study type: Observational

The main objective of the project was to determine the effect of integrated school based deworming and health education on prevalence and morbidity due to co-infection infection with schistosomiasis, STHs and malaria among primary school age children living in rural and farming areas in Zimbabwe There is need for regular school based de-worming and health education programs for the helminths-Plasmodium co-infections in primary schoolchildren living in rural and commercial farming areas in Zimbabwe

NCT ID: NCT01240486 Completed - HIV Clinical Trials

IMPAACT P1073: Study of IRIS for Infants and Children Initiating HAART at Int'l Sites

Start date: November 2010
Phase: N/A
Study type: Observational

Your child is able to participate in this study, if your child's doctor is planning to start your child on HAART (which is a combination of at least 3 anti HIV drugs). When your child is treated with HAART, the way your child's body is able to fight infection may change. The immune system is the body's defense against infection. Your child's immune system may respond in a stronger way to some types of infections that your child may already have. This immune response may cause your child to become sick and the condition is then called "immune reconstitution inflammatory syndrome" or IRIS.